News
Merck & Co's Keytruda outperforms chemo in MSI-High colorect...
Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, offering patients a single-agent therapy opt
